Effect of add on dapagliflozin versus standard-of-care on bone and mineral indices in postmenopausal women with type2 diabetes mellitus: a randomized controlled study

Department of Endocrinology0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Post-menopausal women ( duration of menopause > 5years ) and age < 65 years diagnosed with T2DM and being initiated on SGLT2i shall be enrolled into the study.
•2.Patients on diet alone therapy or with other anti-diabetic agents (metformin, alpha-glucosidase inhibitors, DPP4i or insulin) may be used for achieving glycaemic targets.
•3. HbA1C <10 %
•4.Duration of DM > 5 years

•1. Current users of any of the SGLT2i (Cana or Dapa or Empa )
•2.Patients on bone active agents (anti-resrorptives or osteoanabolics)
•3.Patients on chronic glucocorticoid therapy ( >3 months)
•4.Other drugs (thiazolidinediones, phenytoin, tamoxifen, estrogen, combined OCs)
•5.eGFR <30ml/min/m2
•6.Contraindication or hypersensitivity to SGLT2i
•7.Patients with T1DM, FCPD or known case of secondary diabetes
•8.Pregnant or lactating women
•9.Premature ovarian insufficiency
•10.HbA1C >10%
•11.Known case and/or specific features of CushingÃ¢â?¬•s, AddisonÃ¢â?¬•s, acromegaly, prolactinoma, uncontrolled hypothyroidism, hyperthyroidism, celiac disease, primary hyperparathyroidism
•12.Those unwilling for consent to participate and follow-up

发起方